Cetuximab may be beneficial beyond progression in certain patients with mCRC
the ONA take:
According to new findings presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers have found that continuing second-line cetuximab beyond progression following first-line chemotherapy and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody is beneficial for patients with metastatic colorectal cancer who do not have KRAS, NRAS, BRAF, or PIK3CA gene mutations.
For the phase II study, researchers enrolled 340 patients with metastatic colorectal cancer and KRAS exon 2 wild-type tumors. All participants received first-line treatment with FOLFIRI plus cetuximab until unacceptable toxicity or disease progression. Those who experienced disease progression were then randomly assigned 1:1 to receive second-line FOLFOX plus cetuximab or FOLFOX alone.
Results showed that patients with quadruple wild-type metastatic colorectal cancer had significantly improved progression-free survival, improved overall survival, and improved response rates with the addition of second-line cetuximab. These patients were most likely to have an EGFR-dependent tumor.
The authors note that further studies are warranted to confirm these findings in a larger patient population.
Continuing second-line cetuximab beyond progression following first-line chemo and an anti-EGFR monoclonal antibody is beneficial for quadruple wild-type metastatic
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|